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The KRAS gene (Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) is an oncogene that encodes a small GTPase transductor
protein called KRAS. KRAS is involved in the regulation of cell division as a result of its ability to relay external signals to the cell
nucleus.ActivatingmutationsintheKRASgene impair the ability oftheKRASproteintoswitch between active and inactive states,
leadingtocelltransformationandincreasedresistancetochemotherapyandbiologicaltherapiestargetingepidermalgrowthfactor
receptors. This review highlights some of the features of the KRAS gene and the KRAS protein and summarizes current knowledge
of the mechanism of KRAS gene regulation. It also underlines the importance of activating mutations in the KRAS gene in relation
to carcinogenesis and their importance as diagnostic biomarkers, providing clues regarding human cancer patients’ prognosis and
indicating potential therapeutic approaches.
1.Introduction
In 1982 Chang and Der, two postdoctoral fellows working
in Geoﬀrey Cooper’s laboratory, discovered Kristen Rat Sar-
coma Virus and Murine Sarcoma Virus; retroviral oncogenes
related to rodent sarcoma virus genes. The human KRAS
geneisahomologofthesetwooncogenes[1].Anormalform
ofhumanc-RashasbeencalledKRASorKRAS2(KristenRat
Sarcoma Viral oncogene homolog or alternatively Kristen
Murine Sarcoma Virus2 homolog). In 1983, Der described
an abnormal form of the p21 protein expressed by colon
and lung carcinoma cell lines and showed that the gene
encoding this protein is able to transform NIH3T3 cells [2].
This ﬁnding was later conﬁrmed by Parada and Weinberg
[3], who described the transformation of NIH3T3 cells by
an activated KRAS oncogene. Aberrant p21 proteins were
encoded by the altered KRAS gene and their expression in
carcinoma tissue was causally linked to an abnormal state of
activation [2]. Since then, it has been accepted that KRAS
is one of front-line sensors that initiate the activation of
an array of signalling molecules allowing the transmission
of transducting signals from the cell surface to the nucleus,
thus aﬀecting cell diﬀerentiation, growth, chemotaxis, and
apoptosis. A signal transduction cascade initiated by the
activated form of KRAS is depicted in Figure 1.A sar e s u l t
of these eﬀects, KRAS elicits changes in the cytoskeleton
and consequently aﬀects cell shape, adhesion and migration
[4, 5].
In the following paragraphs, KRAS protein, gene, onco-
genesis, and cancer therapy is reviewed.
2. KRAS Protein
2.1. KRAS Protein Structure, Function, and Localization.
KRAS belongs to a group of small GTP-binding proteins,
known as the RAS superfamily or RAS-like GTPases. More
than 150 RAS-like genes have been identiﬁed in mammalian
genomes [6]. The entire RAS superfamily is characterised
by the presence of a catalytic G domain, but includes
members with distinct evolutionary specializations with
respect to diﬀerent cellular process [7]. The RAS subfamily
(RAS, RHO, RAB, ARF, RAC, and RAN) includes the most
frequently studied proteins, such as Harvey-Ras (H-RAS),
neuroblastoma-Ras (N-RAS), and two variants of Kristen-
RAS (K-RAS)—one, known as KRAS4A, which is weakly
expressed in human cells and the dominant form, known as
KRAS4B, which is much more highly expressed.2 Journal of Biomedicine and Biotechnology
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Figure 1: Signaling pathway of the KRAS protein. Following EGF binding to its receptor and activation of tyrosine kinases, the KRAS
protein becomes activated by binding to GTP, transducing the activation signal to the nucleus by MAPKs and PI3K/AKT-mediated cascades.
Speciﬁcally, the active state of the KRAS protein is facilitated by binding to the Grb2 protein, which interacts with the SH3 domains of the
SOS protein, a member of the nucleotide exchange factor family. In the GTP state, KRAS is able to activate downstream proteins and to
regulate cell transformation.
The KRAS gene product, KRAS protein, contains 188
amino acid residues with a molecular mass of 21.6kD
and participates in intracellular signal transduction [8]. As
mentioned above, the KRAS protein remains inactive until
it binds to GTP, as depicted in Figure 2. The switch from
a ni n a c t i v et oa na c t i v ef o r mi sr e g u l a t e db yi n t r a c e l l u l a r
signals. Once the GTP is bound to the KRAS protein, KRAS
undergoes conformational changes that involve two regions
of the protein, thus activating it. These two important
regions are known as Switch 1 (aminoacids 30–38) and
Switch 2 (aminoacids 59–67), which form an eﬀector loop,
controlling the speciﬁcity of the binding of this GTPase to
its eﬀector molecules. This conformational change in the
KRAS protein aﬀects its interactions with multiple down-
stream transducers—GTPase-activating proteins (GAPs)—
which amplify the GTPase activity of the RAS protein
100,000-fold [9]. The change also aﬀects interactions with
guanine-exchanging/releasing factors (GEFs/GRFs) promot-
ing the release of GTP. The KRAS protein also has intrinsic
GTPase activity, stimulated by GAPs, which acts as a timer
associated with direct interactions with the eﬀectors [10].
Mutations found in an oncogenic form of the RAS p21
protein impair GTPase activity and make the KRAS protein
unresponsive to GAP proteins. Mutated forms of p21 rapidly
exchange GDP for GTP, which it prefers as a substrate, thus
inducing the active state. Such aberrant forms of KRAS
protein deregulate many eﬀectors, thus aﬀecting several
importantcellularpathways.ManyGTPderivativestargeting
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Figure 2: Activity states of the KRAS protein. Mutational change in
exon 1 of KRAS leads to permanent “on” status.
RAS or RAF eﬀectors have been developed to repair the
defective GTPase activity that inﬂuences the aberrant RAS
signalling [11]. However, little is known about the speciﬁcity
and transport of compounds modiﬁed by GTPs through the
plasma membrane.
KRAS contains four domains. The ﬁrst domain includes
85 amino acids at the N-terminus and is identical in the
three forms of RAS (KRAS, NRAS, and HRAS). The secondJournal of Biomedicine and Biotechnology 3
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Figure 3: Model of the KRAS protein with important domains
highlighted. Model of 3GFT molecule was rendered in Swiss-
PdbViewer v4.0.1 (http://spdbv.vital-it.ch/). Switch 1, Switch 2, and
GTP P-loop domains are highlighted by colour change.
domain contains 80 amino acids, with lower sequence iden-
tity (70–80%) among the three forms of RAS protein. These
regionsareimportantforthesignallingfunctionoftheKRAS
protein and jointly form the G-domain (amino acids 1–165,
Figure 3). The G-domain of the KRAS protein includes the
GTP-binding pocket, where P-loop-phosphate binding loops
(aminoacids10–16and56–59)interactwiththeb-phosphate
and c-phosphate of GTP. Residues 116–119 and 152–165
interact with the guanine base. The region between amino
acids 32 and 40 (the core eﬀector region) is essential for
the interactions between the putative downstream eﬀectors
and GAPs. RAS protein also contains a hypervariable region
(HVR) at the C-terminus (amino acids 165–188/189; the
third domain), which guides posttranslational modiﬁcation
and determines plasma membrane anchoring. This region
plays an important role in the regulation of the biological
activity of RAS protein [12].
Switch regions I and II play important roles in the
binding of regulators and eﬀectors. The phosphate binding
pocket-P loop permits temporary binding of GTP to the
RAS protein. This is also the region of GTPase activity,
which negatively regulates the RAS protein via a RAS-GTP
hydrolysis reaction and binding of guanosine diphosphate.
TheKRASproteinactslikeaplasmamembrane-localized
molecular switch, regulating multiple signal transduction
pathways [13]. It is synthesized in the cytosol, where it is far-
nesylated by farnesyl transferase at the cysteine residue of the
carboxy-terminal motif CAAX (where C represents cysteine,
A is an aliphatic amino acid, and X is any amino acid). The
carboxy-terminal motif forms the last domain of the KRAS
protein. The AAX amino acid motif is cleaved by proteases,
whereastheC-terminalcarboxylresidueoftheKRASprotein
ismethylated.CleavageoftheAXXpeptidemotifandmethy-
lation occur at the cytosolic surface of the endoplasmatic
reticulum and are mediated by the RAS-converting enzyme
Rce1 [14]. C-terminal farnesylation plays an important role
in membrane localization. In the splice variant KRAS4A, the
AXXmotifundergoesadditionalpalmitoylationbypalmitoyl
transferase, resulting in proper targeting of KRAS4A to the
membrane. However, there is no detectable palmitoylation
of the predominant splice variant KRAS4B, which probably
reaches the plasma membrane via a microtubule-dependent
mechanism, thus avoiding the Golgi apparatus [13, 15].
Posttranslational farnesylation and carboxymethylation are
believed to be important for the oncogenicity of the RAS
protein. Treatment with farnesyl transferase inhibitors has
been shown to inhibit anchorage-independent growth of
both KRAS-transformed mouse ﬁbroblasts and human
tumour cells containing KRAS and NRAS mutations. Signal
transduction of the KRAS protein does not exclusively
occur at the plasma membrane. Activation of downstream
signalling pathways by KRAS can also be triggered by signals
from subcellular compartments, such as the endoplasmatic
reticulum and the Golgi apparatus [16, 17].
2.2. Why Is the KRAS Protein an Important Target to
Study? While wild-type KRAS usually promotes cell cycle
progression, it can also induce growth arrest, apoptosis,
and replicative senescence when increased to abnormal
levels. This can be triggered by cellular stress, ultraviolet or
ionizingirradiation,heatshock,andsomecytokines.Inthese
circumstances, triggering of growth arrest can represent a
defence mechanism against inappropriate activation of RAS.
It has been demonstrated that the wild-type KRAS gene
is a tumour suppressor that is frequently lost during tumour
progression in many types of cancer [18]. Once the KRAS
gene mutates, it acquires oncogenic properties (Table 1)
and seems to be causally involved in the development
of various human cancers [19, 20]. Loss of the wild-
type KRAS allele has been observed in both human and
mouse tumours, indicating that absence of the normal
allele may facilitate transformation by one copy of the
oncogenic KRAS allele [21]. Oncogenic mutations in the
KRAS gene prevent the hydrolysis of GTP, thus permanently
activating the RAS molecules [22]. Expression of a mutated
KRAS gene in ﬁbroblasts has been shown to augment
metalloproteinase 2 (MMP2) expression in the matrix and
enhance the invasion of cancer cells [23]. Overexpression
of this mutated form of KRAS also inhibits glycosylation of
the integrin β1-chain, resulting in altered polarisation and
increased adhesiveness of colon cancer cells. In addition,
expression of this oncogenic form of KRAS protein has been
shown to be associated with upregulated carcinoembryonic
antigen (CEA) expression and disturbance of epithelial cell
polarization [24].
3. The KRAS gene
3.1. Polymorphism/Structure and Localization of the KRAS
Gene. There are two copies of the KRAS gene in the
human genome, designated KRAS1 and KRAS2. The mRNA
encoded by the main KRAS2 is 5.5kb long, and diﬀers from4 Journal of Biomedicine and Biotechnology
Table 1: Consequences of oncogenic KRAS on cellular physiology
and biology.
RAS eﬀector
pathways
Main function of
the RAS
signalling
pathways
Oncogenic RAS perturb the
intrinsic biochemical
properties of cell pathways
MAPK proliferation increase
PI3K/AKT survival
NORE1/RASSF1 apoptosis deregulation
RAL-GDS membrane vesicle
traﬃcking
JAK/STAT3 growth arrest and
diﬀerentiation
TIAM1/RAC cytoskeletal
organization
PLCε/PKC calcium transport
signalling
AF6 cell-cell junctions
PKCξ transcription
PI3K/PDK1 translation
transcripts of the transforming Kristen murine viral gene
by only six codons [8]. Analysis of human placental and
embryonic cDNA libraries has revealed that 900bp of the
KRAS1 gene is homologous to the corresponding sequence
of the Kristen Murine Sarcoma Virus2 homolog, with one
intervening sequence, and 300bp of the KRAS2 is fully
homologous to the viral counterpart. The KRAS1 gene is
a pseudogene derived from KRAS2 by alternative mRNA
splicing. Therefore, KRAS1 should be oﬃcially named
KRAS1P [8].
In 1983 McBride and colleagues found that the pro-
tooncogenes KRAS1 and KRAS2 are localized at human
chromosomes 6 and 12, respectively [25]. Later, KRAS1 and
KRAS2weremappedbyinsituhybridizationtochromosome
positions 6p11-12 and 12p11.1-12.1, respectively [26].
Sequencing showed that the KRAS2 gene has six exons.
Of these, 2, 3, and 4 are invariant coding exons. Alternative
splicing of exon 4 produces two mRNA forms, known
as 4A and 4B. Exon 5 can be skipped during alternative
splicing, giving rise to isoforms KRASA and KRASB. The
6th exon encodes the C-terminal region in KRASB and is
nottranslated(the3untranslatedregion,3UTR)inKRASA.
KRASB is the predominant splice variant of KRAS2, and is
referred to, brieﬂy, as KRAS [27].
There are indications that allelic losses of chromosome
region 12p commonly occur in human cancers, and a
frequently deleted region is near the KRAS gene at position
12p12-13 [28]. Further, recent studies on lung adenocarci-
nomasuggestthereisanassociationbetweentheincidenceof
alleliclossesinthe12p12-13regionandKRASgenemutation
[29].
3.2. Diagnostics of KRAS Mutations in Human Cancers.
Diagnostics of KRAS gene mutations in clinical setting is
limited by two factors: ﬁrst, in the time of testing, KRAS
mutated tumour cells may be in minority, outbalanced
by wild type tumour cells and wild type non-tumour
cells present in the sample. Second, analytically preferable
snap-frozen tumour samples are rarely available for KRAS
mutation testing. Instead, formalin ﬁxed paraﬃn-embedded
(FFPE) tissue is used. There, integrity of DNA may be
severely compromised by procedure of formalin ﬁxation
(especially by its long duration and low pH).
All the known principles of DNA polymorphism detec-
t i o na r ea p p l i c a b l et oKRAS mutation detection and demand
a dedicated review outside of the scope of this paper. More
than 60 methods described can be divided into sequencing
methods [30–37], methods based on speciﬁc interaction
with oligonucleotide, methods based on speciﬁc interaction
withenzyme [38–40],andconformationalmethods [41–47].
While many speciﬁcity and/or sensitivity enhancement of
methods were described as well [48–53], analytical valida-
tion,systematiccomparison,andassessmentofmethodsside
by side is lacking. To authors best knowledge, only Com-
munaut´ eE u r o p´ eene (CE) marked KRAS mutation detection
kits are supplied by DxS (mutations in codons 12 a 13
are tested using principle of ARMS-PCR [54] and Scorpion
primers [55], Vienna-Lab (reverse dot blot assay format),
TIB Molbiol (KRAS LightMix clamped hybridization probes
forcodon12),andInvigene(qPCRwithsequencesuppressor
agent StopPrimer for the unwanted excess component,
applicable for ﬁrst two nucleotide positions in codons 12
and 13).
3.3. Regulation of KRAS Gene Expression. KRAS expression
is regulated both during the initiation of transcription
by the binding of proteins to its promoter and during
transcriptional elongation by microRNAs aﬀecting KRAS
mRNA stability. Both human and murine KRAS gene
promoters contain a nuclease hypersensitive polypurine-
polypyrimidine element (NHPPE). The G-rich strand of
NHPPE located in the proximal promoter sequence is able to
form an intramolecular parallel G-quadruplex, consisting of
three G-tetrads and three loops, which recognizes and binds
nuclear proteins that are involved in transcriptional repres-
sion of KRAS expression. Accordingly, it has been reported
that sequestration of nuclear proteins that bind to NHPP
by an oligonucleotide mimicking the KRAS G-quadruplex
resulted in 40% inhibition of KRAS transcription, compared
to controls [56].
The transcription of KRAS is regulated, in part, by an
interaction between the promoter region and the 65kDa
ESXR1 protein and, in part, by microRNAs (miRNAs).
ESXR1 is a human protein with an N-terminal home-
odomain in the nucleus and a C-terminal proline-rich repeat
region I in the cytoplasm. The N-terminal fragment of
ESXR1 binds to the TAATGTTATTA consensus sequence
in exon-1 of the KRAS gene, thus inhibiting its mRNA
expression [57]. miRNAs contain a 21-22 nucleotide long
noncoding sequence that is able to regulate gene expression
[58]. In 2005 it was estimated that there are more than
500 miRNAs, which collectively regulate approximately 30%
of all human genes, including the RAS gene family [59].Journal of Biomedicine and Biotechnology 5
Regulation of gene expression by miRNAs probably occurs
as a result of imperfect hybridization of the miRNA to
the complementary sequences located in the 3untranslated
region (3UTR) of target messenger RNA (mRNA) species.
This interaction between miRNA and mRNA both decreases
mRNAstabilityandrepressesproteinsynthesisbypreventing
accesstoribosomes[60].Interestingly,manyalteredmiRNAs
have been identiﬁed in human cancers [61–63], including
some of the most thoroughly analyzed miRNAs—let-7 [64],
lin-4 [65], and bentam [66]—all of which regulate cell
proliferation and diﬀerentiation. Cancer-altered miRNAs
can be divided into two main groups. Members of one
group, the oncomirs, are upregulated in cancer and can
act like oncogenes. The second group, the anti-oncomirs,
probably act as tumour suppressors by targeting oncogenes,
repressing the cell cycle and division of cancer cells [67].
For example, miRNA-let7 is an oncogene-antioncomir pair
that negatively regulates RAS protein levels and decreases
cell proliferation rates [68, 69]. KRAS, NRAS, and HRAS
harbour multiple let-7 miRNA complementary sites (LCSs)
in their 3UTRs [70]. Zhang et al. [18] found that reducing
the activity of let-7 in HeLa cells resulted in a 70% increase
in RAS protein levels, while Takamizawa et al. [68]f o u n d
that let-7 expression was 80% lower in 60% of lung cancer
adenocarcinoma and squamous cell carcinoma lines than
in normal lung tissue. Moreover, a correlation between low
levels of let-7 miRNA and signiﬁcantly higher RAS protein
expressionhasbeenfoundinlungsquamouscellcarcinomas.
These results suggest that let-7 is able to downregulate the
expression of RAS in human carcinomas.
These molecular ﬁndings provide a strong rationale for
developing novel therapeutic treatments aimed at decreasing
KRAS protein expression in cancer cells. In many cases
KRAS protein expression is dramatically increased due to
mutations in the KRAS gene sequence, thus making cells
refractory to current therapies, such as those involving use
of epidermal growth factor receptor inhibitors [71].
4. KRAS in Oncogenesis
Activating KRAS gene point mutations have been detected in
many types of human tumours [72]. Such oncogenic forms
of the KRAS gene are prevalent in pancreatic carcinomas
(>80%), colon carcinomas (40–50%), and lung carcinomas
(30–50%), but are also present in biliary tract malignancies,
endometrial cancer, cervical cancer, bladder cancer, liver
cancer, myeloid leukemia [73, 74] and breast cancer [75].
Mutations in the KRAS gene have important eﬀects on
the process of carcinogenesis, which depend on the cells and
tissues involved [76]. The mutations found most frequently
in the KRAS gene of cancer cells are located at positions
12 and 13 in exon 1, and less frequently in codons 61, 63,
117, 119, and 146 [77, 78]. These mutations are located near
to the GTP binding site. Allelic mutations result in amino
acid changes, namely Gly to Asp, Ala, Arg, Ser, Val, or Cys
in codon 12 and Gly to Asp in codon 13 [79]. Somatic
missense mutations at positions 12, 13, 61, and 63 enable
perturbation of the intrinsic GTPase activity of the KRAS
12 Gly
Figure 4: Position of codon 12 in KRAS molecule. Wild type
aminoacid at codon 12 is shown in green.
protein, resulting in reductions in GTP hydrolysis capacity.
Mutations in codons 12 (Figure 4) or 13 are known to lead to
conformational changes in the KRAS protein.
Mutation in codon 12 of the KRAS gene causes the
encoded KRAS protein to “freeze” in its active state for a
muchlongerdurationthanitsnonmutatedcounterpart[11].
Mutations resulting in the substitution of amino acids 116,
117, 119, and 146 reduce the nucleotide aﬃnity of the KRAS
protein, thereby aﬀecting the rate of GDP/GTP exchange.
The oncogenic forms of the RAS protein have a profound
eﬀect on the downstream eﬀector pathways, resulting in
much higher proliferation rates of cancer cells expressing
such forms.
The transforming ability of the KRAS oncogene may
resultfromoverexpressionofthemutantKRASalleleorfrom
deletionofthewild-typeallele[80].OverexpressionofKRAS
can also be induced by the loss of p16INK4 (CDKN2A),
p19INK4 (CDKN2D), or p53 [81]. However, studies by
Zhang et al. (2001) have shown that the wild-type KRAS
allele can suppress the oncogenic function of the mutated
allele [18].
In addition, the radiosensitivity of tumour cells is altered
by oncogenic RAS expression, probably as a result of the
eﬀect of the KRAS mutation on several intercommunicating
pathways [82].
4.1. Pancreatic Cancer. The prevalence of mutations in the
KRAS gene at the time of diagnosis is highest in pancreatic
cancers (>80% of cases), notably pancreatic adenocarcino-
mas predominantly harbour KRAS forms with a guanine to
thymine transversion in codon 12 [83]. Wei and colleagues
examined samples collected from 30 patients with pancreatic
cancerandfoundthat24ofthemshowedmutationsatcodon
12 and only one at codon 13 [84]. However, concurrent
KRASmutationsfrequentlyoccurinpatientswithpancreatic
cancer [85]. A positive association has been found in
patients with pancreatic cancer between tobacco exposure6 Journal of Biomedicine and Biotechnology
and mutations in the KRAS gene [86]. Similar associations
have also been reported for coﬀee drinking [87], and milk,
butter, and alcohol consumption [88, 89]. However, no
direct evidence of a causal relationship between these dietary
components and mutations in the KRAS gene has been
presented.
4.2. Colon Cancer. The second highest incidence (about
50% of cases) of mutations in the KRAS gene is found in
colon cancers [90, 91]. The progression of colon carcinomas
can be divided into at least three stages. The ﬁrst stage is
characterized by the development of a small, benign tubular
type of adenoma or polyp with sporadically detectable KRAS
mutation(s) [92]. The second stage is more aggressive and
is usually associated with patches of deﬁnitive carcinoma
cells,whichmaygrowintoinvasivecancerscharacterisingthe
third stage. Mutations of the KRAS gene have been identiﬁed
in tissues from both adenoma and carcinoma cases, but at
much lower frequencies in colon adenoma tissues than in
carcinoma tissues [93, 94]. The incidence of mutation in the
KRAS gene has been found to be low and to occur mainly in
the small adenomas of patients with familial adenomatous
polyposis, who have a predisposition to colon cancer [94]
in the KRAS gene associated with colon cancer appear most
often in codons 12 (28%) and 13 (8%) of exon 1 and
less frequently in codon 61 [95]. In colorectal cancer, the
main substitution (Gly to Asp) has been found to occur
in codon 12. Mutation from GGT (Gly) to GTT (Val) in
codon 12 has been observed more frequently in primary
metastatic carcinoma, suggesting that this mutation may
confer a more aggressive phenotype in colorectal carcinoma
[96]. A mutation in codon 13, resulting in the substitution
of Gly with Asp, observed in colon cancer has been shown
to be associated with reduced survival rates [97]. This kind
of KRAS gene mutation has also been shown to occur
more frequently in unstable, than in stable, colon tumours
[97, 98].
4.3. Lung Cancer. Losses of KRAS wild type alleles in both
mouse and human lung adenocarcinomas and squamous
carcinomas have been found in many studies, notably in
67% to 100% of chemically induced murine lung adeno-
carcinoma cases harbouring a mutant KRAS. In humans,
KRAS mutations appear in 10–30% of lung carcinoma cases,
demonstrating strong associations with a history of smoking
[99]andpoorprognosis[100,101].Amongbothcurrentand
former smokers, KRAS gene mutations have been identiﬁed
in 30% of lung adenocarcinoma cases. Further, although
some researchers have found sporadic KRAS mutations in
non-smokers with early onset of cancer, smoking history
is an important factor and is correlated with increased
occurrence of mutations in the KRAS gene in lung cancer
cases[102].MutationsintheKRASgene incodons 12and 13
were detected in 21% of NSCLC (non-small cell lung cancer)
tumour samples examined in the TRIBUTE III trial [103].
NSCLC patients have a tendency to accumulate activating
mutations in either the EGFR or KRAS genes. However, a
clinical study has shown that mutations of these two genes
are,ingeneral,mutuallyexclusive.EGFRmutationsaremore
often found in patients who have no history of smoking.
4.4. Breast Cancer. Although higher KRAS mutational fre-
quency is primarily found in cancers of the pancreas,
colon and lung, possible links between KRAS hyper-
activity and human breast cancer have been explored
recently. Hollestelle at al. found mutations in 12.5% of
cases [104] but the Sanger COSMIC database version
28 (http://www.sanger.ac.uk/genetics/CGP/cosmic/)r e c o r d s
only a 5% incidence [105]. The lower frequency of KRAS
mutations in breast cancer cell lines suggests that the gene
mutation may be less important in breast cancer carcino-
genesis than in other forms of cancer, although mutations
at a “hotspot” in the KRAS gene have been found in a small
subset of breast cancers.
5. KRAS and Cancer Therapy
5.1. Tyrosine Kinase Inhibitors of the EGFR1 Gene. Many
clinical trials have shown that a poorer response to
chemotherapy, a shorter time-to-progression, and worse
overall survival are consistently associated with speciﬁc
mutations in oncogenes. KRAS is one of the most frequently
mutated oncogenes in many cancers, and it is also one of the
most important predictors of resistance to targeted therapy
using EGFR1 tyrosine kinase inhibitors (EGFR-TKIs) [106].
Two of the most important EGFR-speciﬁc TKIs are
geﬁtinib (Iressa, ZD1839) and erlotinib (Tarceva). The ﬁrst
indications of the predictive strength of the association
between the KRAS gene and therapeutic responses to the
EGFR-TKI geﬁtinib were originally observed in NSCLC
patients with tumours bearing the wild-type form of
the KRAS gene and constitutively activated EGFR1 gene,
due to activating mutations in exons 18 to 21 or high
copy number/ampliﬁcation of the EGFR1 gene. Clinically,
better responses to tyrosine kinase inhibitor treatment
were observed in patients with adenocarcinomas and well-
diﬀerentiated tumours, female patients, non-smokers, and
people of Asiatic origin [107–109]. Clinical research data
show that geﬁtinib monotherapy is well tolerated and active
against a wide range of tumour types, including colon, head,
neck, breast, prostate, and lung cancers, especially NSCLCs
[110].
EGFR-TKIs are usually used as the second line therapy
in patients after failure of chemotherapy. However, geﬁtinib
did not pass the registration procedure in the European
Unionbecauseinsuﬃcientclinicalbeneﬁtwasdemonstrated,
probablybecauseEuropeanclinicaltrialsdidnotincludesuf-
ﬁcient “good responders” (Asians, women, adenocarcinoma
patientsandnon-smokers).Clinicaldataalsosuggestthatthe
drugrepresentsanewtherapeuticoptionforNSCLCpatients
with brain metastases [111].
After the successful TRIBUTE and TALENT clinical
trials, erlotinib (Tarceva) was also approved by the US FDA
in 2002 as a second or third line treatment for NSCLC
after failure of standard chemotherapy. However, molecular
analysis revealed that patients who have activating mutationsJournal of Biomedicine and Biotechnology 7
in the KRAS gene (exon 1: codons 12, 13, or 61) with or
without increases in EGFR copy numbers did not derive
beneﬁt from this therapy and had about a 96% chance of
disease progression [71].
Similarly, Eberhard et al. ﬁrst observed the relationship
between KRAS mutations and the outcome of erlotinib
therapy in a randomized phase III clinical trial in which the
drugwasused,incombinationwithﬁrstline“goldstandard”
chemotherapy(carboplatinandpaclitaxel),totreatadvanced
NSCLC patients [103]. Patients with the KRAS mutation
exhibited a shorter time to progression (three months) and
a shorter overall survival (four months) when treated with
a combination of erlotinib and ﬁrst line chemotherapy,
such as treatment with cisplatin, compared to the group
with wild-type KRAS, for whom the time-to-progression
was 12 months. Most NSCLC patients in the erlotinib
treatment study had expressed wild-type KRAS, and their
KRAS status had greater prognostic than predictive value as
ab i o m a r k e r[ 112]. However, in colorectal cancer, mutations
in the KRAS gene are important predictive (as well as
prognostic) biomarkers, since the eﬀectiveness of treatment
with cetuximab and panitumumab is impaired in tumours
with the activating mutation. Information regarding the
status of the KRAS gene allows the selection of appropriate
therapies for patients who do not display activating muta-
tions and the selection of alternative therapies for patients
with mutations. Although results pertaining to the role of
KRAS in the prognosis of clinical outcome or prediction of
therapeutic responses to EGFR1 tyrosine kinase inhibitors
are interesting, they need to be validated in larger and
prospective trials, using standardized and sensitive mutation
detection techniques. If the associations are conﬁrmed,
knowledge of the mutation status of KRAS in NSCLC
tumours could help physicians decide which patients should
receive geﬁtinib and/or erlotinib.
Interestingly, KRAS gene mutations also seem to provide
strongpredictiveindicationoftherapeuticresponsestoother
classes of tyrosine kinase inhibitors, as recently demon-
strated for the imatinib mesylate (Glivec). Imatinib is the
standard drug for patients with chronic myeloid leukaemia
(CML) and patients with gastrointestinal stromal tumours
(GISTs), expressing the bcr-abl fusion protein and tyrosine
kinase receptor c-kit, respectively. Further, drug resistance to
imatinib is usually attributed to mutation of the imatinib-
binding sites of these proteins [113], although ampliﬁcation
of the bcr-abl fusion gene or overexpression of multidrug
resistance proteins may be involved in some cases [114].
However, a recent study by Agarwal et al. demonstrated
that CML patients resistant to imatinib frequently expressed
mutated KRAS proteins [115].
5.2. Monoclonal Antibodies as EGFR1 Inhibitors. Colorectal
cancer is another frequent neoplasia that is associated with
activation of the EGFR1 pathway, so it is not surprising that
novel and successful therapeutic strategies for this condition
involve EGFR1 protein kinase inhibition. In contrast to
NSCLC, two monoclonal antibodies against EGFR1, rather
than small molecular inhibitors of EGFR1, are generally used
for treating colorectal cancer: cetuximab (Erbitux)a n d
panitumumab (Vectibix). In accordance with the eﬀect of
small molecular EGFR1 inhibitors in NSCLC, KRAS alter-
ations play a critical role in the response of colorectal cancer
patients to such therapeutic monoclonal antibodies. Indeed,
KRAS mutation status is the most important predictor of
resistance to cetuximab or panitumumab; both the median
progression-free survival of cetuximab-treated patients and
overall survival was recently found to be superior in a
KRAS wild-type group than in a KRAS mutant group (31
versus 10 weeks, and 16 versus 7 months, respectively)
[116]. On September 27, 2006, the US FDA approved
the completely humanized monoclonal anti-EGFR1 IgG2
antibody—panitumumab (Vectibix) for clinical use in the
third line treatment of patients with metastatic colorectal
carcinomawhohadprogressedafterstandardchemotherapy.
KRAS Panitumumab therapy was tested in a randomized
study involving 463 patients [117], and the results showed
that the wild-type KRAS gene is essential for its therapeutic
activity. Progression-free survival of patients with wild-type
versus mutant KRAS gene tumours was 12 versus seven
weeks, while response rates obtained in another study were
17% versus 0% [118]. These ﬁndings strongly indicate that
KRAS gene status should be routinely tested as a critically
important diagnostic biomarkertodetermine whichpatients
will derive therapeutic beneﬁt from EGFR1 inhibition.
Indeed, analysis of the KRAS gene status in colorectal cancer
cases has become conditio sinequa non for deciding whether
or not to apply cetuximab or panitumumab therapy in
routine clinical practice and FDA has updated Vectibix and
Erbitux labels in 2009 to include this information.
5.3. Chemotherapy and Radiation. Surprisingly, the eﬀects
of KRAS gene mutations on tumour sensitivity to cytotoxic
chemotherapies and radiation have only been explored in a
few studies. However, expression of a 12 Val mutated form of
KRAS has been shown to increase the resistance of cancer
cells to radiation therapy [119]. Similarly, the presence of
oncogenic KRAS has been found to signiﬁcantly increase
the sensitivity of cells to a novel class of anticancer agents,
cucurbitacins, in a p53- or p21-dependent manner [120].
In contrast, an ovarian cancer cell line TOV-21G bearing
am u t a n ta l l e l eo fKRAS is reportedly signiﬁcantly more
sensitive to cisplatin and radiation, but not to paclitaxel or
campthotecin, than the corresponding KRAS wild type line
[121].
However, results of clinical studies by Rosell and col-
leagues (1995) showed that patients with a mutation in
the KRAS gene had poorer clinical responses to paclitaxel
monotherapy than wild type controls, suggesting that KRAS
gene status is a predictive marker of paclitaxel resistance
[122]. In a phase III retrospective study on NSCLC patients
(TRIBUTE), randomly treated with carboplatin and pacli-
taxel with erlotinib or placebo, patients with KRAS mutant
tumours showed poorer clinical outcomes when treated with
erlotinib plus chemotherapy compared to chemotherapy
alone [103]. An updated clinical trial (CRYSTAL) involv-
ing 540 metastatic colorectal cancer patients demonstrated8 Journal of Biomedicine and Biotechnology
that cetuximab in combination with FOLFIRI (folic acid,
ﬂuorouracil, and irinotecan) in ﬁrst line therapy is highly
eﬀective against KRAS wild type, but not mutant, tumours.
However, further analysis of the data showed that neither the
response nor the progression-free survival of patients treated
withchemotherapyaloneweresigniﬁcantlyaﬀectedbyKRAS
gene status, although the overall survival of patients with
KRAS mutant tumours was signiﬁcantly shorter than that
of patients with KRAS wild type tumours [123]. Recently
we have also shown that EGFR may represent a predic-
tive molecular marker for poor response to preoperative
chemoradiotherapy in locally advanced gastric carcinoma
[124]. Responses to chemoradiotherapy were found in 60%
of EGFR-negative patients, but only 13% of EGFR-positive
patients (P = .044), and pathologic complete responses were
observed in 29% of patients with EGFR-negative staining,
but none (of eight) EGFR-positive patients (P = .16).
The above ﬁndings regarding the role of the KRAS
gene in tumour responses to cytotoxic therapies appear
to conﬂict somewhat. The predictive and prognostic sig-
niﬁcance of oncogenic KRAS seems to have been mixed
in many studies, and the contributions of variations in
the gene to clinical outcome appear to diﬀer according
to tumour types and therapeutic interventions. Clearly,
further studies are urgently needed to conﬁrm and clarify
the ﬁndings in large prospective biomarker-oriented clinical
trials.
5.4. Angiogenesis Inhibitors. Other clinical trials have also
demonstrated that activating mutations in the KRAS gene
can contribute to tumour progression by aﬀecting the
expression of vascular endothelial growth factor (VEGF),
which plays a critical role in tumour angiogenesis. Inhibition
of KRAS expression by selected KRAS antisense oligonu-
cleotides has been shown to be associated with signiﬁ-
cantly reduced secretion of VEGF-A165 into the medium
of colorectal cancer cell cultures [125]. In addition, in a
cohort of patients with pancreatic tumours, 25/33 (76%)
with KRAS mutations showed higher VEGF expression, and
their median survival was shorter, than those with tumours
expressing the wild-type allele [126]. Similar ﬁndings have
also been reported from a study of NSCLCs, in which
higher VEGF expression was observed in 50% of tumours
bearing a KRAS gene mutation [127]. Although these studies
suggest that KRAS gene status could play an important role
in responses to anti-VEGF targeted antiangiogenic therapy,
a recent study by Hurwitz and Saini [128] showed that
groups of patients bearing either KRAS mutant or wild-type
tumours derive therapeutic beneﬁt from ﬁrst line applica-
tion of the anti-VEGF monoclonal antibody bevacizumab
(Avastin). Furthermore, although both groups of patients
(i.e., those with wild-type KRAS and mutated KRAS genes)
beneﬁted from adding bevacizumab to chemotherapy, both
progression-free survival and survival was better for wild-
type KRAS patients, both with chemotherapy alone and
with chemotherapy plus bevacizumab. Bevacizumab did not
increase the percentage of patients with mutated KRAS who
responded to treatment.
5.5. Future Therapies. An optimal therapeutic drug should
be able to speciﬁcally target the mutated KRAS gene or its
product, have minimal systemic toxicity and be orally active.
Unfortunately, drugs like this remain to be developed and
less eﬃcient strategies need to be used in clinical trials.
However, in addition to the cancer therapies mentioned
above, several therapeutic agents and strategies can directly
suppress the activating mutant form of the KRAS gene, and
thus improve the eﬃciency of chemotherapy and biological
therapy.
One possible approach for inhibiting KRAS expression
is to use antisense oligonucleotides or viral constructs
delivering antisense sequences in order to inactivate the
mutant oncogene RNA message [125]. In addition, synthesis
of mutated KRAS protein has been repressed by applying
a small interfering adenovirus-mediated RNA (siRNA), and
thespeciﬁcallydesignedsiRNAwasshowntohaveprolonged
anti-proliferative eﬀects against various tumour cancer cell
lines expressing mutated KRAS proteins [129]. Another,
s i m i l a rs t r a t e g yt ot a r g e tm u t a n tK R A Sm R N Ai sb a s e d
on designing an mRNA ribozyme that speciﬁcally interacts
with a mutated form of the KRAS mRNA and encodes
catalytic RNA molecules that bind to the mRNA substrate
by base-pair complementation, leading to translation arrest
and/or degradation of the speciﬁc mRNA. The KRAS-
speciﬁc ribozyme strategy has also been shown to suppress
successfully the proliferation of KRAS-mutated tumour cells
[130].
Recently an interesting novel strategy employing farne-
syltransferase inhibitors (FTIs) was shown to inhibit the
biochemical transactivation initiated by the mutated KRAS
gene. Farnesyl transferase is an enzyme that primarily
regulates zinc metabolism by the addition of a farnesyl group
to the cysteine residue of a protein. At least 30 proteins
(including KRAS) require posttranslational farnesylation to
reach their membrane positions and function properly in
cell signalling. Farnesyl inhibitors represent a novel class of
biologically active anticancer drugs that inhibit cell growth.
After the discovery that RAS proteins have to be farnesylated
to become functionally active, several farnesyl inhibitors
were developed. However, Phase II and Phase III clinical
trials conducted to date have found that KRAS FTIs might
not be suﬃcient to inhibit the mutated-overactive forms of
KRAS protein. The reason for this is probably incomplete
inhibition of farnesylation, because garnesylation of KRAS
protein by geranyltransferase I leads to suppression of the
eﬀects of farnesyltransferase inhibitors [131, 132].
It should be noted that although KRAS inhibitory strate-
gies have shown promise in preclinical trials and have been
partiallysuccessfulinclinicaltrials,thereareinsuﬃcientdata
on their eﬃcacy in combination with anti-EGFR1 strategies
to recommend their routine use as yet.
6. Conclusions
The evidence from various studies summarized in this
review demonstrates that the KRAS protein is an important
signal transducer involved in the regulation of variousJournal of Biomedicine and Biotechnology 9
cellular responses during cell proliferation, diﬀerentiation,
and survival. A pivotal function of KRAS protein in the
regulation of the MAPK and PI3K/AKT pathways is its eﬀect
on the proliferation rate of both normal and cancer cells.
Activating mutations of the KRAS protein, which frequently
occurincancercells,indicatepoorerprognosisandincreased
resistance to some cancer therapies.
Overall, this review summarizes novel approaches allow-
ing the management of cancers with or without KRAS muta-
tions,andhighlightstheimportanceofearlyidentiﬁcationof
somatic mutations in the KRAS gene in cancer biopsies. The
latter assists oncologists to select the best available therapies
for their cancer patients.
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